TSE:4568Pharmaceuticals
Daiichi Sankyo (TSE:4568) Is Up 5.5% After EU Pan-Tumor Enhertu Approval And ADC Milestones
Daiichi Sankyo and AstraZeneca recently secured a European Commission approval for Enhertu across multiple HER2 positive metastatic solid tumors and received an EMA committee recommendation for Datroway as first-line treatment for certain triple-negative breast cancer patients, alongside board decisions on share-based compensation.
These oncology milestones expand Daiichi Sankyo’s European treatment footprint, trigger a US$25 million milestone payment from AstraZeneca, and reinforce the...